DEBRA Research and UMC Groningen Unveil Clinical Trial Site for Epidermolysis Bullosa

DEBRA Research GmbH, a non-profit focused on Epidermolysis bullosa (EB) research, has partnered with the University Medical Center Groningen (UMCG) to launch a new clinical trial site dedicated to EB. This initiative aims to bolster research infrastructure globally, offering increased access to studies and fostering patient-centered research.

The collaboration enhances clinical trial capacity within a region recognized for its expertise in EB care. Led by Dr. Marieke C. Bolling, the Groningen site will conduct various EB clinical trials and participate in international initiatives like the EB Registry.

Furthermore, DEBRA supports the COSEB project to standardize outcome measurements in EB research, aiming for robust and comparable clinical trial data. Dr. Bolling emphasizes international collaboration to advance effective therapies for EB patients, while DEBRA’s Christoph Coch highlights strengthening trial capacity as a key enabler for progress.